BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33627038)

  • 1. The addition of iguratimod can reduce methotrexate dose in rheumatoid arthritis with clinical remission.
    Yoshikawa A; Kotani T; Matsuda S; Hata K; Matsumura Y; Takeuchi T
    Mod Rheumatol; 2022 Jan; 32(1):68-73. PubMed ID: 33627038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical effectiveness of iguratimod based on real-world data of patients with rheumatoid arthritis.
    Mizutani S; Kodera H; Sato Y; Nanki T; Yoshida S; Yasuoka H
    Clin Rheumatol; 2021 Jan; 40(1):123-132. PubMed ID: 32506311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The three-year efficacy of iguratimod in clinical daily practice in patients with rheumatoid arthritis.
    Suto T; Yonemoto Y; Okamura K; Sakane H; Takeuchi K; Tamura Y; Kaneko T; Ayabe K; Chikuda H
    Mod Rheumatol; 2019 Sep; 29(5):775-781. PubMed ID: 30092680
    [No Abstract]   [Full Text] [Related]  

  • 4. Add-on effectiveness of methotrexate or iguratimod in patients with rheumatoid arthritis exhibiting an inadequate response to Janus kinase inhibitors: The ANSWER cohort study.
    Ebina K; Hirano T; Maeda Y; Okita Y; Etani Y; Hirao M; Yamamoto W; Hashimoto M; Murata K; Onishi A; Jinno S; Hara R; Son Y; Amuro H; Kotani T; Shiba H; Katayama M; Yamamoto K; Kumanogoh A; Okada S; Nakata K
    Mod Rheumatol; 2023 Jul; 33(4):690-699. PubMed ID: 35962543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: A retrospective study.
    Yoshikawa A; Yoshida S; Kimura Y; Tokai N; Fujiki Y; Kotani T; Matsumura Y; Takeuchi T; Makino S
    Mod Rheumatol; 2018 Mar; 28(2):227-234. PubMed ID: 28644744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iguratimod versus salazosulfapyridine in rheumatoid arthritis patients with an inadequate response to methotrexate: Adjusted with propensity score matching.
    Nozaki Y; Oribe M; Tomita D; Itami T; Hayashi S; Maeda T; Fukuda K; Kuroda R; Funahashi K; Matsubara T; Kinoshita K; Matsumura I
    Mod Rheumatol; 2023 Apr; 33(3):472-480. PubMed ID: 35695707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of the clinical use of iguratimod therapy in patients with rheumatoid arthritis.
    Okamura K; Yonemoto Y; Okura C; Kobayashi T; Takagishi K
    Mod Rheumatol; 2015 Mar; 25(2):235-40. PubMed ID: 25065917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial.
    Hara M; Ishiguro N; Katayama K; Kondo M; Sumida T; Mimori T; Soen S; Nagai K; Yamaguchi T; Yamamoto K;
    Mod Rheumatol; 2014 May; 24(3):410-8. PubMed ID: 24252050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease activity early in treatment as a predictor of future low disease activity in RA patients treated with iguratimod.
    Yoshioka Y; Takahashi N; Kaneko A; Hirano Y; Kanayama Y; Kanda H; Takagi H; Ito T; Kato T; Saito K; Funahashi K; Asai S; Takemoto T; Terabe K; Asai N; Ishiguro N; Kojima T
    Mod Rheumatol; 2016; 26(2):169-74. PubMed ID: 26140467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iguratimod for the treatment of rheumatoid arthritis in Japan.
    Tanaka K; Yamaguchi T; Hara M
    Expert Rev Clin Immunol; 2015 May; 11(5):565-73. PubMed ID: 25797025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The add-on effectiveness and safety of iguratimod in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab.
    Ebina K; Miyama A; Tsuboi H; Kaneshiro S; Nishikawa M; Owaki H; Tsuji S; Hirao M; Etani Y; Goshima A; Hashimoto J; Yoshikawa H
    Mod Rheumatol; 2019 Jul; 29(4):581-588. PubMed ID: 29882440
    [No Abstract]   [Full Text] [Related]  

  • 12. The effects of iguratimod combined with methotrexate and hydroxychloroquine on bone mineral density in patients with rheumatoid arthritis.
    Yu JJ; Wu F; Ma RR; Wu TJ; Zhang Y; Ying ZH
    Pharmazie; 2021 Oct; 76(10):507-510. PubMed ID: 34620280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effectiveness and Retention Rate of Iguratimod in Japanese Rheumatoid Arthritis Patients with/without Methotrexate in Daily Medical Care.
    Inoue A; Nozaki Y; Hirooka Y; Kinoshita K; Chiba Y; Funauchi M; Matsumura I
    Life (Basel); 2020 Oct; 10(11):. PubMed ID: 33138014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of add-on iguratimod in patients with rheumatoid arthritis who inadequately respond to either tocilizumab or tumor necrosis factor alpha inhibitors.
    Hattori K; Hirano Y; Kanayama Y; Hattori Y; Kato T; Takahashi N; Ishiguro N; Kojima T
    Mod Rheumatol; 2021 Jan; 31(1):80-87. PubMed ID: 32148143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and Safety of Iguratimod Monotherapy or Combined With Methotrexate in Treating Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
    Ouyang D; Ma YZ; Zou J; Wang YL; Chen Z; Yang YY; Zou B; Li X; Cao JZ
    Front Pharmacol; 2022; 13():911810. PubMed ID: 35991879
    [No Abstract]   [Full Text] [Related]  

  • 16. Effectiveness of iguratimod as monotherapy or combined therapy in patients with rheumatoid arthritis: a systematic review and meta-analysis of RCTs.
    Hu CJ; Zhang L; Zhou S; Jiang N; Zhao JL; Wang Q; Tian XP; Zeng XF
    J Orthop Surg Res; 2021 Jul; 16(1):457. PubMed ID: 34271950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iguratimod dose dependently inhibits the expression of citrullinated proteins and peptidylarginine deiminases 2 and 4 in neutrophils from rheumatoid arthritis patients.
    Li B; Li P; Bi L
    Clin Rheumatol; 2020 Mar; 39(3):899-907. PubMed ID: 31758423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy of methotrexate and iguratimod for female patients with moderate to severe active rheumatoid arthritis and its impact on ovarian function.
    Jingzhou Z; Xiong Z; Xin KQ
    Pak J Pharm Sci; 2023 Sep; 36(5(Special)):1657-1662. PubMed ID: 38008964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of iguratimod combined with methotrexate vs. methotrexate alone in rheumatoid arthritis : A systematic review and meta-analysis of randomized controlled trials.
    Chen LJ; Zhou YJ; Wen ZH; Tian F; Li JY
    Z Rheumatol; 2021 Jun; 80(5):432-446. PubMed ID: 33346891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iguratimod in combination with methotrexate in active rheumatoid arthritis : Therapeutic effects.
    Xia Z; Lyu J; Hou N; Song L; Li X; Liu H
    Z Rheumatol; 2016 Oct; 75(8):828-833. PubMed ID: 26508503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.